Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension

Abstract Objective. To compare the efficacy and safety of olmesartan medoxomil (O) and ramipril (R) in elderly patients with essential arterial hypertension. Methods. After a 2-week placebo washout, 351 elderly hypertensive patients aged 65–89 years (office sitting diastolic blood pressure, DBP, 90–109 mmHg and office sitting systolic blood pressure, SBP, 140–179 mmHg) were randomized double-blind to 12-week treatment with O 10 mg or R 2.5 mg once daily. After the first 2 and 6 weeks, doses could be doubled in non-normalized (blood pressure <140/90 mmHg for non-diabetic and <130/80 mmHg for diabetic) subjects, up to 40 mg for O and 10 mg for R. Office blood pressures were assessed at randomization, after 2, 6 and 12 weeks of treatment; 24-h ambulatory blood pressure (ABP) was recorded at randomization and after 12 weeks. Results. At week 12, in the intention-to-treat population (170 patients O and 175 R) the rate of normalized subjects was significantly larger in the O group (38.8% vs 26.3% R; p = 0.013). Baseline-adjusted mean sitting office blood pressure reduction at final visit was not significantly greater under O [SBP: 16.6 (95% confidence interval 14.0/19.2) mmHg vs 13.0 (10.4/15.6) mmHg R, p = 0.206; DBP: 11.8 (10.3/13.3) mmHg vs 10.5 (9.0/12.0) mmHg, p = 0.351]. In the subgroup of patients with valid ABP recordings (38 O and 47 R), the reduction in 24-h average blood pressure was significantly (p < 0.01) larger with O [SBP: 8.9 (9.8/8.1) and DBP: 5.7 (6.3/5.1) mmHg] than with R [6.7 (7.9/5.6) and 4.4 (5.1/3.7) mmHg]. The superiority of O was particularly evident in the last 4 h from the dosing interval. The proportion of patients with drug-related adverse events was comparable in the two groups (4.0% O vs 4.5% R), as well as the number of patients discontinuing study drug because of a side-effect (8 O vs 7 R). Conclusions. In elderly patients with essential arterial hypertension, O provides an effective, prolonged and well tolerated blood pressure control, with significantly better blood pressure normalization than R and represents a useful option among first-line drug treatments of hypertension in this age group.

[1]  L. Scott,et al.  Olmesartan Medoxomil , 2012, Drugs.

[2]  J. Mallion,et al.  Use of Ambulatory Blood Pressure Monitoring in the Management of Antihypertensive Therapy , 2012, Drugs.

[3]  W. Elliott.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2010 .

[4]  S. Rosas,et al.  MORBIDITY AND MORTALITY , 2010 .

[5]  M. Destro,et al.  Olmesartan medoxomil: recent clinical and experimental acquisitions , 2009, Expert opinion on drug metabolism & toxicology.

[6]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[7]  Jackson T. Wright,et al.  Drug treatment of hypertension in older hypertensives. , 2009, Clinics in geriatric medicine.

[8]  P. Gosse,et al.  Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials , 2009, Journal of Human Hypertension.

[9]  A. Unger,et al.  Prevalence, Awareness, and Management of Hypertension, Dyslipidemia, and Diabetes Among United States Adults Aged 65 and Older , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  J. Mallion,et al.  Olmesartan Medoxomil in Elderly Patients with Essential or Isolated Systolic Hypertension , 2009, Drugs & Aging.

[11]  G. Parati,et al.  Italian Society of Hypertension Guidelines for Conventional and Automated Blood Pressure Measurement in the Office, at Home and Over 24 Hours , 2008, High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension.

[12]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[13]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[14]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[15]  L. Scott,et al.  Olmesartan medoxomil: a review of its use in the management of hypertension. , 2008, Drugs.

[16]  J. Mallion,et al.  Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension , 2007, Journal of hypertension.

[17]  Margaret Carroll,et al.  Trends in Hypertension Prevalence, Awareness, Treatment, and Control in Older U.S. Adults: Data from the National Health and Nutrition Examination Survey 1988 to 2004 , 2007, Journal of the American Geriatrics Society.

[18]  J. Redón,et al.  Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring , 2007, Journal of hypertension.

[19]  S. Neldam,et al.  Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. , 2006, The American journal of geriatric cardiology.

[20]  L. Sellin,et al.  Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension , 2005, Journal of hypertension.

[21]  D. Lloyd‐Jones,et al.  Hypertension in adults across the age spectrum: current outcomes and control in the community. , 2005, JAMA.

[22]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[23]  David H. G. Smith,et al.  Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[24]  P. Palatini,et al.  Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. , 2004, Clinical therapeutics.

[25]  A. Coats,et al.  Ambulatory pressure monitoring in the assessment of antihypertensive therapy , 1989, Cardiovascular Drugs and Therapy.

[26]  P. Palatini,et al.  A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. , 2003, Clinical therapeutics.

[27]  J. Sanderson,et al.  Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. , 2003, Clinical therapeutics.

[28]  Yutaka Imai,et al.  Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults , 2002, Blood pressure monitoring.

[29]  B. Prichard,et al.  Eprosartan versus Enalapril in Elderly Patients with Hypertension: a Doubleblind, Randomized Trial , 2001, Blood pressure.

[30]  S. Neldam,et al.  Antihypertensive Treatment in Elderly Patients Aged 75 Years or Over , 2001, Drugs & aging.

[31]  Y. Lacourciére.  A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. , 2000, Clinical therapeutics.

[32]  J. Neutel,et al.  Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. , 2000, Clinical therapeutics.

[33]  J. Staessen,et al.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.

[34]  S. Oparil,et al.  Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. , 1999, American journal of therapeutics.

[35]  G. Parati,et al.  The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension , 1998, Journal of hypertension.

[36]  G. Parati,et al.  The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension. , 1998, Blood pressure monitoring.

[37]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[38]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[39]  D. Rizzoni.  Beyond trough:peak ratio: a new index of the smoothness of the antihypertensive effect of a drug , 1996 .

[40]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[41]  J. Edelman,et al.  Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. , 1995, Clinical therapeutics.

[42]  G. Parati,et al.  Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.

[43]  ECiM 6BQ,et al.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. , 1992, BMJ.

[44]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[45]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[46]  J. Coope,et al.  Randomised trial of treatment of hypertension in elderly patients in primary care. , 1987, British medical journal.

[47]  L. Kuller,et al.  Systolic Hypertension in the Elderly Program (SHEP) , 1986, Journal of the American Geriatrics Society.

[48]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.